U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H14N4O5S
Molecular Weight 398.3943
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of SULFASALAZINE

SMILES

c1ccnc(c1)NS(=O)(=O)c2ccc(cc2)/N=N/c3ccc(c(c3)C(=O)O)O

InChI

InChIKey=NCEXYHBECQHGNR-QZQOTICOSA-N
InChI=1S/C18H14N4O5S/c23-16-9-6-13(11-15(16)18(24)25)21-20-12-4-7-14(8-5-12)28(26,27)22-17-3-1-2-10-19-17/h1-11,23H,(H,19,22)(H,24,25)/b21-20+

HIDE SMILES / InChI

Molecular Formula C18H14N4O5S
Molecular Weight 398.3943
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Description
Curator's Comment:: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/007073s124lbl.pdf

Sulfasalazine is an anti-inflammatory indicated for the treatment of ulcerative colitis and rheumatoid arthritis. The mode of action of Sulfasalazine or its metabolites, 5-aminosalicylic acid (5-ASA) and sulfapyridine (SP), is still under investigation, but may be related to the anti-inflammatory and/or immunomodulatory properties that have been observed in animal and in vitromodels, to its affinity for connective tissue, and/or to the relatively high concentration it reaches in serous fluids, the liver and intestinal walls, as demonstrated in autoradiographic studies in animals. In ulcerative colitis, clinical studies utilizing rectal administration of Sulfasalazine, SP and 5-ASA have indicated that the major therapeutic action may reside in the 5-ASA moiety. The relative contribution of the parent drug and the major metabolites in rheumatoid arthritis is unknown. Sulfasalazine is used for the treatment of Crohn's disease and rheumatoid arthritis as a second-line agent. Sulfasalazine is marketed under the trade name Azulfidine among others.

CNS Activity

Curator's Comment:: sulfasalazine can effectively penetrate the blood-brain barrier (BBB)

Originator

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
AZULFIDINE

Approved Use

AZULFIDINE EN-tabs Tablets are indicated: a) in the treatment of mild to moderate ulcerative colitis, and as adjunctive therapy in severe ulcerative colitis; b) for the prolongation of the remission period between acute attacks of ulcerative colitis; c) in the treatment of patients with rheumatoid arthritis who have responded inadequately to salicylates or other nonsteroidal anti-inflammatory drugs (e.g., an insufficient therapeutic response to, or intolerance of, an adequate trial of full doses of one or more nonsteroidal anti-inflammatory drugs); and in the treatment of pediatric patients with polyarticular-course 1 juvenile rheumatoid arthritis who have responded inadequately to salicylates or other nonsteroidal antiinflammatory drugs.

Launch Date

-616550400000
Primary
AZULFIDINE

Approved Use

AZULFIDINE EN-tabs Tablets are indicated: a) in the treatment of mild to moderate ulcerative colitis, and as adjunctive therapy in severe ulcerative colitis; b) for the prolongation of the remission period between acute attacks of ulcerative colitis; c) in the treatment of patients with rheumatoid arthritis who have responded inadequately to salicylates or other nonsteroidal anti-inflammatory drugs (e.g., an insufficient therapeutic response to, or intolerance of, an adequate trial of full doses of one or more nonsteroidal anti-inflammatory drugs); and in the treatment of pediatric patients with polyarticular-course 1 juvenile rheumatoid arthritis who have responded inadequately to salicylates or other nonsteroidal antiinflammatory drugs.

Launch Date

-616550400000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
12.9 μg/mL
2 g single, oral
dose: 2 g
route of administration: Oral
experiment type: SINGLE
co-administered:
SULFASALAZINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
98 μg × h/mL
2 g single, oral
dose: 2 g
route of administration: Oral
experiment type: SINGLE
co-administered:
SULFASALAZINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
27.4 μM × h
6.5 mmol single, rectal
dose: 6.5 mmol
route of administration: Rectal
experiment type: SINGLE
co-administered:
SULFASALAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.6 h
2 g single, oral
dose: 2 g
route of administration: Oral
experiment type: SINGLE
co-administered:
SULFASALAZINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
7.6 h
unknown, intravenous
SULFASALAZINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
25 g single, oral
Overdose
Dose: 25 g
Route: oral
Route: single
Dose: 25 g
Sources:
unhealthy, 23
Health Status: unhealthy
Age Group: 23
Sex: M
Sources:
Disc. AE: Headache, Dizziness...
AEs leading to
discontinuation/dose reduction:
Headache
Dizziness
Sources:
50 g single, oral
Overdose
Dose: 50 g
Route: oral
Route: single
Dose: 50 g
Sources:
unhealthy, 26
Health Status: unhealthy
Age Group: 26
Sex: M
Sources:
Disc. AE: Lactic acidosis, Seizures...
AEs leading to
discontinuation/dose reduction:
Lactic acidosis (severe)
Seizures
Coagulopathy
Hyperglycemia
Ketosis
Methemoglobinemia
Sources:
1 g 3 times / day multiple, oral
Recommended
Dose: 1 g, 3 times / day
Route: oral
Route: multiple
Dose: 1 g, 3 times / day
Sources:
unhealthy, 43
Health Status: unhealthy
Age Group: 43
Sex: M+F
Sources:
Disc. AE: Headache, Headache...
AEs leading to
discontinuation/dose reduction:
Headache (severe, 16.7%)
Headache (8.3%)
Nausea (12.5%)
Nausea (severe, 8.3%)
Acute pancreatitis (4.2%)
Abdominal pain (4.2%)
Lethargy (4.2%)
Depression (8.3%)
Dizziness (severe, 4.2%)
Rash (4.2%)
Light headedness (4.2%)
Sources:
1 g 2 times / day multiple, oral
Recommended
Dose: 1 g, 2 times / day
Route: oral
Route: multiple
Dose: 1 g, 2 times / day
Sources:
unhealthy, 8.4 ±4.4
Health Status: unhealthy
Age Group: 8.4 ±4.4
Sex: M+F
Sources:
Disc. AE: Toxic reaction (NOS), Anorexia...
AEs leading to
discontinuation/dose reduction:
Toxic reaction (NOS) (serious, 2.9%)
Anorexia (serious, 2.9%)
Nausea (serious, 2.9%)
Abdominal discomfort (serious, 2.9%)
Headache (serious, 2.9%)
Fever (serious, 2.9%)
Rash (serious, 2.9%)
Lymphadenopathy cervical (serious, 2.9%)
Leukopenia (5.7%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Dizziness Disc. AE
25 g single, oral
Overdose
Dose: 25 g
Route: oral
Route: single
Dose: 25 g
Sources:
unhealthy, 23
Health Status: unhealthy
Age Group: 23
Sex: M
Sources:
Headache Disc. AE
25 g single, oral
Overdose
Dose: 25 g
Route: oral
Route: single
Dose: 25 g
Sources:
unhealthy, 23
Health Status: unhealthy
Age Group: 23
Sex: M
Sources:
Coagulopathy Disc. AE
50 g single, oral
Overdose
Dose: 50 g
Route: oral
Route: single
Dose: 50 g
Sources:
unhealthy, 26
Health Status: unhealthy
Age Group: 26
Sex: M
Sources:
Hyperglycemia Disc. AE
50 g single, oral
Overdose
Dose: 50 g
Route: oral
Route: single
Dose: 50 g
Sources:
unhealthy, 26
Health Status: unhealthy
Age Group: 26
Sex: M
Sources:
Ketosis Disc. AE
50 g single, oral
Overdose
Dose: 50 g
Route: oral
Route: single
Dose: 50 g
Sources:
unhealthy, 26
Health Status: unhealthy
Age Group: 26
Sex: M
Sources:
Methemoglobinemia Disc. AE
50 g single, oral
Overdose
Dose: 50 g
Route: oral
Route: single
Dose: 50 g
Sources:
unhealthy, 26
Health Status: unhealthy
Age Group: 26
Sex: M
Sources:
Seizures Disc. AE
50 g single, oral
Overdose
Dose: 50 g
Route: oral
Route: single
Dose: 50 g
Sources:
unhealthy, 26
Health Status: unhealthy
Age Group: 26
Sex: M
Sources:
Lactic acidosis severe
Disc. AE
50 g single, oral
Overdose
Dose: 50 g
Route: oral
Route: single
Dose: 50 g
Sources:
unhealthy, 26
Health Status: unhealthy
Age Group: 26
Sex: M
Sources:
Nausea 12.5%
Disc. AE
1 g 3 times / day multiple, oral
Recommended
Dose: 1 g, 3 times / day
Route: oral
Route: multiple
Dose: 1 g, 3 times / day
Sources:
unhealthy, 43
Health Status: unhealthy
Age Group: 43
Sex: M+F
Sources:
Abdominal pain 4.2%
Disc. AE
1 g 3 times / day multiple, oral
Recommended
Dose: 1 g, 3 times / day
Route: oral
Route: multiple
Dose: 1 g, 3 times / day
Sources:
unhealthy, 43
Health Status: unhealthy
Age Group: 43
Sex: M+F
Sources:
Acute pancreatitis 4.2%
Disc. AE
1 g 3 times / day multiple, oral
Recommended
Dose: 1 g, 3 times / day
Route: oral
Route: multiple
Dose: 1 g, 3 times / day
Sources:
unhealthy, 43
Health Status: unhealthy
Age Group: 43
Sex: M+F
Sources:
Lethargy 4.2%
Disc. AE
1 g 3 times / day multiple, oral
Recommended
Dose: 1 g, 3 times / day
Route: oral
Route: multiple
Dose: 1 g, 3 times / day
Sources:
unhealthy, 43
Health Status: unhealthy
Age Group: 43
Sex: M+F
Sources:
Light headedness 4.2%
Disc. AE
1 g 3 times / day multiple, oral
Recommended
Dose: 1 g, 3 times / day
Route: oral
Route: multiple
Dose: 1 g, 3 times / day
Sources:
unhealthy, 43
Health Status: unhealthy
Age Group: 43
Sex: M+F
Sources:
Rash 4.2%
Disc. AE
1 g 3 times / day multiple, oral
Recommended
Dose: 1 g, 3 times / day
Route: oral
Route: multiple
Dose: 1 g, 3 times / day
Sources:
unhealthy, 43
Health Status: unhealthy
Age Group: 43
Sex: M+F
Sources:
Depression 8.3%
Disc. AE
1 g 3 times / day multiple, oral
Recommended
Dose: 1 g, 3 times / day
Route: oral
Route: multiple
Dose: 1 g, 3 times / day
Sources:
unhealthy, 43
Health Status: unhealthy
Age Group: 43
Sex: M+F
Sources:
Headache 8.3%
Disc. AE
1 g 3 times / day multiple, oral
Recommended
Dose: 1 g, 3 times / day
Route: oral
Route: multiple
Dose: 1 g, 3 times / day
Sources:
unhealthy, 43
Health Status: unhealthy
Age Group: 43
Sex: M+F
Sources:
Headache severe, 16.7%
Disc. AE
1 g 3 times / day multiple, oral
Recommended
Dose: 1 g, 3 times / day
Route: oral
Route: multiple
Dose: 1 g, 3 times / day
Sources:
unhealthy, 43
Health Status: unhealthy
Age Group: 43
Sex: M+F
Sources:
Dizziness severe, 4.2%
Disc. AE
1 g 3 times / day multiple, oral
Recommended
Dose: 1 g, 3 times / day
Route: oral
Route: multiple
Dose: 1 g, 3 times / day
Sources:
unhealthy, 43
Health Status: unhealthy
Age Group: 43
Sex: M+F
Sources:
Nausea severe, 8.3%
Disc. AE
1 g 3 times / day multiple, oral
Recommended
Dose: 1 g, 3 times / day
Route: oral
Route: multiple
Dose: 1 g, 3 times / day
Sources:
unhealthy, 43
Health Status: unhealthy
Age Group: 43
Sex: M+F
Sources:
Leukopenia 5.7%
Disc. AE
1 g 2 times / day multiple, oral
Recommended
Dose: 1 g, 2 times / day
Route: oral
Route: multiple
Dose: 1 g, 2 times / day
Sources:
unhealthy, 8.4 ±4.4
Health Status: unhealthy
Age Group: 8.4 ±4.4
Sex: M+F
Sources:
Abdominal discomfort serious, 2.9%
Disc. AE
1 g 2 times / day multiple, oral
Recommended
Dose: 1 g, 2 times / day
Route: oral
Route: multiple
Dose: 1 g, 2 times / day
Sources:
unhealthy, 8.4 ±4.4
Health Status: unhealthy
Age Group: 8.4 ±4.4
Sex: M+F
Sources:
Anorexia serious, 2.9%
Disc. AE
1 g 2 times / day multiple, oral
Recommended
Dose: 1 g, 2 times / day
Route: oral
Route: multiple
Dose: 1 g, 2 times / day
Sources:
unhealthy, 8.4 ±4.4
Health Status: unhealthy
Age Group: 8.4 ±4.4
Sex: M+F
Sources:
Fever serious, 2.9%
Disc. AE
1 g 2 times / day multiple, oral
Recommended
Dose: 1 g, 2 times / day
Route: oral
Route: multiple
Dose: 1 g, 2 times / day
Sources:
unhealthy, 8.4 ±4.4
Health Status: unhealthy
Age Group: 8.4 ±4.4
Sex: M+F
Sources:
Headache serious, 2.9%
Disc. AE
1 g 2 times / day multiple, oral
Recommended
Dose: 1 g, 2 times / day
Route: oral
Route: multiple
Dose: 1 g, 2 times / day
Sources:
unhealthy, 8.4 ±4.4
Health Status: unhealthy
Age Group: 8.4 ±4.4
Sex: M+F
Sources:
Lymphadenopathy cervical serious, 2.9%
Disc. AE
1 g 2 times / day multiple, oral
Recommended
Dose: 1 g, 2 times / day
Route: oral
Route: multiple
Dose: 1 g, 2 times / day
Sources:
unhealthy, 8.4 ±4.4
Health Status: unhealthy
Age Group: 8.4 ±4.4
Sex: M+F
Sources:
Nausea serious, 2.9%
Disc. AE
1 g 2 times / day multiple, oral
Recommended
Dose: 1 g, 2 times / day
Route: oral
Route: multiple
Dose: 1 g, 2 times / day
Sources:
unhealthy, 8.4 ±4.4
Health Status: unhealthy
Age Group: 8.4 ±4.4
Sex: M+F
Sources:
Rash serious, 2.9%
Disc. AE
1 g 2 times / day multiple, oral
Recommended
Dose: 1 g, 2 times / day
Route: oral
Route: multiple
Dose: 1 g, 2 times / day
Sources:
unhealthy, 8.4 ±4.4
Health Status: unhealthy
Age Group: 8.4 ±4.4
Sex: M+F
Sources:
Toxic reaction (NOS) serious, 2.9%
Disc. AE
1 g 2 times / day multiple, oral
Recommended
Dose: 1 g, 2 times / day
Route: oral
Route: multiple
Dose: 1 g, 2 times / day
Sources:
unhealthy, 8.4 ±4.4
Health Status: unhealthy
Age Group: 8.4 ±4.4
Sex: M+F
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer








Drug as perpetrator​Drug as victim
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

Initial Therapy :
Route of Administration: Oral
In Vitro Use Guide
Inhibition of arachidonate 5-lipoxygenase by sulfasalazine and its major metabolites was observed at higher concentrations (2-3 mM).
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:10:59 UTC 2021
Edited
by admin
on Fri Jun 25 21:10:59 UTC 2021
Record UNII
3XC8GUZ6CB
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SULFASALAZINE
EP   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
USAN   INN  
Official Name English
SULFASALAZINE [USAN]
Common Name English
SULFASALAZINE [INN]
Common Name English
SULFASALAZINE [ORANGE BOOK]
Common Name English
SALAZOSULFAPYRIDINE [JAN]
Common Name English
SULFASALAZINE [WHO-DD]
Common Name English
SALAZOPYRIN
Brand Name English
SULFASALAZINE [EP MONOGRAPH]
Common Name English
SULFASALAZINE [MART.]
Common Name English
SULFASALAZINE [MI]
Common Name English
SULFASALAZINE [USP-RS]
Common Name English
SULFASALAZINE [VANDF]
Common Name English
SULFASALAZINUM [WHO-IP LATIN]
Common Name English
SULFASALAZINE [USP]
Common Name English
AZULFIDINE
Brand Name English
SALICYLAZOSULFAPYRIDINE
Common Name English
NSC-203730
Code English
NSC-667219
Code English
BENZOSULFA
Common Name English
SULFASALAZINE [IARC]
Common Name English
SULFASALAZOPYRIDINE
Common Name English
SULFASALAZINE [WHO-IP]
Common Name English
2-HYDROXY-5-((4-((2-PYRIDINYLAMINO)SULFONYL)PHENYL)AZO)BENZOIC ACID [WHO-IP]
Common Name English
BENZOIC ACID, 2-HYDROXY-5-(2-(4-((2-PYRIDINYLAMINO)SULFONYL)PHENYL)DIAZENYL)-
Systematic Name English
SULFASALAZINE [HSDB]
Common Name English
SULPHASALAZINE
Common Name English
Classification Tree Code System Code
NDF-RT N0000005760
Created by admin on Fri Jun 25 21:10:59 UTC 2021 , Edited by admin on Fri Jun 25 21:10:59 UTC 2021
NDF-RT N0000005760
Created by admin on Fri Jun 25 21:10:59 UTC 2021 , Edited by admin on Fri Jun 25 21:10:59 UTC 2021
WHO-VATC QA07EC01
Created by admin on Fri Jun 25 21:10:59 UTC 2021 , Edited by admin on Fri Jun 25 21:10:59 UTC 2021
NCI_THESAURUS C257
Created by admin on Fri Jun 25 21:10:59 UTC 2021 , Edited by admin on Fri Jun 25 21:10:59 UTC 2021
LIVERTOX 912
Created by admin on Fri Jun 25 21:10:59 UTC 2021 , Edited by admin on Fri Jun 25 21:10:59 UTC 2021
NDF-RT N0000005760
Created by admin on Fri Jun 25 21:10:59 UTC 2021 , Edited by admin on Fri Jun 25 21:10:59 UTC 2021
NDF-RT N0000175781
Created by admin on Fri Jun 25 21:10:59 UTC 2021 , Edited by admin on Fri Jun 25 21:10:59 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 2.4
Created by admin on Fri Jun 25 21:10:59 UTC 2021 , Edited by admin on Fri Jun 25 21:10:59 UTC 2021
WHO-ATC A07EC01
Created by admin on Fri Jun 25 21:10:59 UTC 2021 , Edited by admin on Fri Jun 25 21:10:59 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 17.3
Created by admin on Fri Jun 25 21:10:59 UTC 2021 , Edited by admin on Fri Jun 25 21:10:59 UTC 2021
NDF-RT N0000005760
Created by admin on Fri Jun 25 21:10:59 UTC 2021 , Edited by admin on Fri Jun 25 21:10:59 UTC 2021
Code System Code Type Description
MESH
D012460
Created by admin on Fri Jun 25 21:10:59 UTC 2021 , Edited by admin on Fri Jun 25 21:10:59 UTC 2021
PRIMARY
EPA CompTox
599-79-1
Created by admin on Fri Jun 25 21:10:59 UTC 2021 , Edited by admin on Fri Jun 25 21:10:59 UTC 2021
PRIMARY
FDA UNII
3XC8GUZ6CB
Created by admin on Fri Jun 25 21:10:59 UTC 2021 , Edited by admin on Fri Jun 25 21:10:59 UTC 2021
PRIMARY
NCI_THESAURUS
C29469
Created by admin on Fri Jun 25 21:10:59 UTC 2021 , Edited by admin on Fri Jun 25 21:10:59 UTC 2021
PRIMARY
INN
2210
Created by admin on Fri Jun 25 21:10:59 UTC 2021 , Edited by admin on Fri Jun 25 21:10:59 UTC 2021
PRIMARY
CAS
599-79-1
Created by admin on Fri Jun 25 21:10:59 UTC 2021 , Edited by admin on Fri Jun 25 21:10:59 UTC 2021
PRIMARY
DRUG CENTRAL
2525
Created by admin on Fri Jun 25 21:10:59 UTC 2021 , Edited by admin on Fri Jun 25 21:10:59 UTC 2021
PRIMARY
USP_CATALOG
1636005
Created by admin on Fri Jun 25 21:10:59 UTC 2021 , Edited by admin on Fri Jun 25 21:10:59 UTC 2021
PRIMARY USP-RS
EVMPD
SUB20720
Created by admin on Fri Jun 25 21:10:59 UTC 2021 , Edited by admin on Fri Jun 25 21:10:59 UTC 2021
PRIMARY
RXCUI
9524
Created by admin on Fri Jun 25 21:10:59 UTC 2021 , Edited by admin on Fri Jun 25 21:10:59 UTC 2021
PRIMARY RxNorm
EVMPD
SUB10727MIG
Created by admin on Fri Jun 25 21:10:59 UTC 2021 , Edited by admin on Fri Jun 25 21:10:59 UTC 2021
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
SULFASALAZINE
Created by admin on Fri Jun 25 21:10:59 UTC 2021 , Edited by admin on Fri Jun 25 21:10:59 UTC 2021
PRIMARY Description: A bright yellow to brownish yellow powder; odourless. Solubility: Practically insoluble in water and ether R; very slightly soluble in ethanol (~750 g/l) TS; soluble in alkali hydroxides. Category: Antibacterial drug. Storage: Sulfasalazine should be kept in a tightly closed container, protected from light. Additional information: Sulfasalazine melts at about 255?C with decomposition. Definition: Sulfasalazine contains not less than 93.0% and not more than 103.0% of C18H14N4O5S, calculated with reference to the dried substance.
DRUG BANK
DB00795
Created by admin on Fri Jun 25 21:10:59 UTC 2021 , Edited by admin on Fri Jun 25 21:10:59 UTC 2021
PRIMARY
HSDB
3395
Created by admin on Fri Jun 25 21:10:59 UTC 2021 , Edited by admin on Fri Jun 25 21:10:59 UTC 2021
PRIMARY
ECHA (EC/EINECS)
209-974-3
Created by admin on Fri Jun 25 21:10:59 UTC 2021 , Edited by admin on Fri Jun 25 21:10:59 UTC 2021
PRIMARY
MERCK INDEX
M10343
Created by admin on Fri Jun 25 21:10:59 UTC 2021 , Edited by admin on Fri Jun 25 21:10:59 UTC 2021
PRIMARY Merck Index
ChEMBL
CHEMBL421
Created by admin on Fri Jun 25 21:10:59 UTC 2021 , Edited by admin on Fri Jun 25 21:10:59 UTC 2021
PRIMARY
IUPHAR
4840
Created by admin on Fri Jun 25 21:10:59 UTC 2021 , Edited by admin on Fri Jun 25 21:10:59 UTC 2021
PRIMARY
WIKIPEDIA
Sulfasalazine
Created by admin on Fri Jun 25 21:10:59 UTC 2021 , Edited by admin on Fri Jun 25 21:10:59 UTC 2021
PRIMARY
LACTMED
Sulfasalazine
Created by admin on Fri Jun 25 21:10:59 UTC 2021 , Edited by admin on Fri Jun 25 21:10:59 UTC 2021
PRIMARY
Related Record Type Details
TRANSPORTER -> INHIBITOR
TARGET -> AGONIST
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
TRANSPORTER -> SUBSTRATE
TARGET -> INHIBITOR
TRANSPORTER -> INHIBITOR
TARGET -> INHIBITOR
TRANSPORTER -> INHIBITOR
TARGET -> INHIBITOR
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
EP
Related Record Type Details
METABOLITE ACTIVE -> PARENT
Inhibite the Hb-catalyzed peroxidative reaction
METABOLITE INACTIVE -> PARENT
Not inhibite the Hb-catalyzed peroxidative reaction
METABOLITE -> PARENT
METABOLITE LESS ACTIVE -> PARENT
Inhibite the Hb-catalyzed peroxidative reaction
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC